Transgene S.A. Deal History & Licensing Activity
Transgene S.A. is a life sciences. Over the past three years, Transgene S.A. has been involved in 1 licensing and acquisition transaction, with a primary focus on Vaccines (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Vaccines
Focus Area
Oncology
Transgene S.A. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Transgene S.A. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AI-based neoantigen prediction platform | NEC Bio B.V. | Vaccines | Phase 2 | license | Apr 2026 |
Transgene S.A. Pipeline Focus
Therapeutic areas and modalities where Transgene S.A. is most active based on deal history and clinical trial data.
See How Your Asset Matches Transgene S.A.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Vaccines Benchmarks
Upfront, milestone, and royalty benchmarks for vaccines deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Transgene S.A. Licensing & Deal Activity
Transgene S.A. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Transgene S.A. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Transgene S.A. include Oncology (2 deals and trials). In terms of modality, Transgene S.A. has shown particular interest in vaccines.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Transgene S.A. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Transgene S.A.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.